A Phase 2, Open-label, Multicenter, Exploratory Safety, Tolerability, Pharmacokinetic, and Efficacy Study of SPD489 in Preschool Children Aged 4-5 Years with Attention Deficit/Hyperactivity Disorder

Administered By

Awarded By

Contributors

Start/End

  • June 1, 2015 - April 18, 2017